Baxter (BAX) Declares $0.115 Quarterly Dividend; 1.2% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St slips as higher yields and oil prices flag inflation risk
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
Baxter Declares Quarterly Dividend
July 29, 2015 4:10 PM EDTDEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX) today declared a regular quarterly dividend of $0.115 per Baxter common share. This cash dividend is payable on October 1, 2015 to shareholders of record as of September 4, 2015.
This dividend represents the new quarterly dividend rate for Baxter following its successful spin-off of its biopharmaceuticals business, Baxalta Incorporated, on July 1, 2015. Over its 84-year history, Baxter has consistently paid a dividend to shareholders and followed a disciplined approach to capital allocation that balances reinvestment in the businesses with returning significant value to shareholders.
''This quarterly dividend is... More
Baxter Reports Strong Second Quarter Financial Results Exceeding Guidance
July 29, 2015 4:05 PM EDTCompany Achieves Significant Milestone with Successful Completion of Baxalta Incorporated Spin-Off, Poised for Profitable Growth
DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX) today reported second quarter financial results that exceeded the companys previously issued guidance, and provided its complete financial outlook for the second half of 2015. The results for the second quarter of 2015 include the companys BioScience business, which was officially spun-off on July 1st and is now operating as a publicly traded biopharmaceutical company, Baxalta Incorporated (NYSE: BXLT).... More



